AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential
AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential
AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential
AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential
AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential
AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential
AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential
AI Powered Mental Health Diagnostics  - Low Risk High Profit Potential

AI Powered Mental Health Diagnostics - Low Risk High Profit Potential

₹1370

AI Powered Mental Health Diagnostics ✌️【Risk】✌️From ₹500 to massive profits. Start investing now for high returns!

quantity
Add to Wishlist
Product Description

AI Powered Mental Health Diagnostics ✌️【Risk】✌️From ₹500 to massive profits. Start investing now for high returns!

AI Powered Mental Health Diagnostics ✌️【Risk】✌️From ₹500 to massive profits. Start investing now for high returns!Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

AI Powered Mental Health Diagnostics ✌️【Risk】✌️Start with ₹500 and enjoy up to 100% returns monthly. Make your money work for you!We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

AI Powered Mental Health Diagnostics ✌️【Risk】✌️Start with ₹500 and grow your wealth through blockchain and AI-powered investments!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

AI Powered Mental Health Diagnostics ✌️【Risk】✌️Begin with ₹500 and earn fast, safe returns month after month.The underperformance persists despite a 22.AI Powered Mental Health Diagnostics ✌️【Risk】✌️Smart investments start with ₹500. Grow your wealth with minimal risk!

Related Products